유의한 황반부종이 있는 비증식당뇨망막병증 환자의 범망막광응고술과 베바시주맙병합치료의 장기효과
The Effect of Intravitreal Bevacizumab Injection before Panretinal Photocoagulation in Patients with Clinically Significant Macular Edema
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
목적: 유의한 황반부종(clinically significant macular edema, CSME)이 있는 환자에서 범망막광응고술(panretinal photocoagulation, PRP) 전 시행한 유리체 내 베바시주맙 주입의 효과를 알아보고자 하였다. 대상과 방법: CSME가 있는 심한 비증식당뇨망막병증 환자(91안, 70명)의 의무기록을 후향적으로 분석, PRP 단독군(51안)과 PRP 전유리체 내 베바시주맙 주입술(1.25 mg/0.05 mL)을 시행한 군(병합치료군, 40안)으로 분류하였다. 치료 시작 전, 치료 후 1, 3, 6, 12개월째 최대교정시력과 중심황반두께를 측정하였다. 결과: 평균 최대교정시력(logMAR, 괄호 내 Snellen)은 PRP군이 치료 전 0.24 (0.575), 1, 3, 6, 12개월째 각각 0.27 (0.537), 0.28 (0.525), 0.28 (0.525), 0.30 (0.501) (p=0.13, 0.15, 0.56, 0.79), 병합치료군은 0.32 (0.479), 0.25 (0.562), 0.26 (0.549), 0.27 (0.537), 0.36 (0.436) (p=0.02, 0.04, 0.02, 0.13)이었다. 평균 중심황반두께(μm)는 PRP군이 257.66, 285.16, 282.21, 289.65, 309.85 (p=0.00, 0.00, 0.00, 0.00), 병합치료군은 349.39, 312.17, 331.15. 353.30, 333.55 (p=0.04, 0.94, 0.79, 0.06)였다. 결론: CSME가 있는 환자에서 PRP를 시행할 때 병합치료는 단독치료에 비해 3개월 이내 단기간의 황반부종 억제효과 및 6개월까지의시력호전을 보였다.
Abstract
Purpose: To determine the effect of intravitreal bevacizumab injection before panretinal photocoagulation (PRP) in clinically significant macular edema (CSME) patients. Methods: A total of 91 eyes (70 patients) having severe nonproliferative diabetic retinopathy with CSME requiring PRP were enrolled in the present study; the medical records were retrospectively reviewed and analyzed. The eyes were divided into the regular PRP group (51 eyes) and PRP with preinjection of bevacizumab (1.25 mg) group (combination group, 40 eyes) and compared. Best corrected visual acuity (BCVA) and central macular thickness (CMT) at pretreatment and 1, 3, 6, and 12 months after PRP was evaluated. Results: BCVA (logarithm of the minimum angle of resolution, Snellen visual acuity in parentheses) at pretreatment and 1, 3, 6, and 12 months after PRP was 0.24 (0.575), 0.27 (0.537), 0.28 (0.525), 0.28 (0.525), and 0.30 (0.501) (p = 0.13, 0.15, 0.56 and 0.79) in the regular PRP group and 0.32 (0.479), 0.25 (0.562), 0.26 (0.549), 0.27 (0.537), and 0.36 (0.436) (p = 0.02, 0.04, 0.02 and 0.13) in the combination group, respectively. CMT (μm) at pretreatment and 1, 3, 6, and 12 months after PRP was 257.66, 285.16, 282.21, 289.65, and 309.85 (p = 0.00, 0.00, 0.00 and 0.00) in the regular PRP group and 349.39, 312.17, 331.15. 353.30, and 333.55 (p = 0.04, 0.94, 0.79 and 0.06) in the combination group, respectively. Conclusions: Pretreatment of anti-vascular endothelial growth factor injection before PRP affected the decrease of macular thickness for 3 months after PRP and improved visual acuity for 6 months after PRP when compared with PRP alone in patients with CSME.
참고문헌 (21)
- Massin P., "Safety and efficacy of ranibizumab in diabetic macular edema(RESOLVE Study) : a 12-month, randomized, controlled, double-masked, multicenter phase II study", Diabetes Care, 33, pp.2399~2405 (2010)
- Soheilian M., "Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema", Ophthalmology, 116, pp.1142~1150 (2009)
- Photocoagulation treatment of proliferative diabetic retinopathy., "Clinical application of Diabetic Retinopathy Study(DRS)findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group", Ophthalmology, 88, pp.583~600 (1981)
- McDonald HR., "Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy", Ophthalmology, 92, pp.388~393 (1985)
- Mason JO 3rd., "Intravitreal bevacizumab(Avastin)prevention of panretinal photocoagulationinduced complications in patients with severe proliferative diabetic retinopathy", Retina, 28, pp.1319~1324 (2008)
- "Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group", Ophthalmology, 98(5 Suppl), pp.766~785 (1991)
- 태기선, "당뇨망막병증환자에서 범망막광응고술 후 단기간 임상경과", 대한안과학회지, 44(9), pp.7~2003 (2003), 대한안과학회
- Cho WB., "Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy", Retina, 29, pp.516~522 (2009)
- 최준호, "고위험 증식당뇨망막병증에서 범망막광응고술과 유리체강내 베바시주맙 병합치료의 장기간 효과", 대한안과학회지, 51(6), pp.842~848 (2010), 대한안과학회
- Avery RL., "Regression of retinal and iris neovascularization after intravitreal bevacizumab(Avastin)treatment", Retina, 26, pp.352~354 (2006)
- Cho WB., "Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy", Br J Ophthalmol, 94, pp.858~863 (2010)
- McDonald HR., "Macular edema following panretinal photocoagulation", Retina, 5, pp.5~10 (1985)
- Nonaka A., "Inflammatory response after scatter laser photocoagulation in nonphotocoagulated retina", Invest Ophthalmol Vis Sci, 43, pp.1204~1209 (2002)
- Brooks HL Jr., "Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone", Arch Ophthalmol, 122, pp.1801~1807 (2004)
- Haritoglou C., "Intravitreal bevacizumab(Avastin)therapy for persistent diffuse diabetic macular edema", Retina, 26, pp.999~1005 (2006)
- Jeon S., "Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates", Clin Ophthalmol, 8, pp.1479~1486 (2014)
- Ju Hwan Song, "Comparison of the Short-Term Effects of Intravitreal Triamcinolone Acetonide and Bevacizumab Injection for Diabetic Macular Edema", Korean Journal of Ophthalmology, 25(3), pp.156~160 (2011), 대한안과학회
- Diabetic Retinopathy Clinical Research Network., "A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema", Ophthalmology, 114, pp.1860~1867 (2007)
- Kook D., "Long-term effect of intravitreal bevacizumab(avastin)in patients with chronic diffuse diabetic macular edema", Retina, 28, pp.1053~1060 (2008)
- Arevalo JF., "Comparison of two doses of primary intravitreal bevacizumab(Avastin)for diffuse diabetic macular edema : results from the Pan-American Collaborative Retina Study Group(PACORES)at 12-month follow-up", Graefes Arch Clin Exp Ophthalmol, 247, pp.735~743 (2009)
- Roh MI., "Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema", Retina, 28, pp.1314~1318 (2008)